Development and validation of novel DNA tests for diagnosis applicable in clinical practice
Project is carried out within the European Regional Development Fund (ERDF) activity "Support for science and research"
Project identification no: ERDF 2DP/126.96.36.199.0/10/APIA/VIAA/022
Project activity period: 36 months (01.01.2011.-31.12.2013.)
Projekt costs: 409 860,00 LVL
Principle investigator: Dr. biol. Jānis Kloviņš
The general aim of the project: Introduce the genetic testing for diagnosis of lipid disorders and coronary heart disease (CHD) risks in Latvia, help to prevent CHD, increase longevity of Latvian population, increase competitiveness of biopharma industry and export growth in Latvia.
Specific aim of the project: Develop the innovative genetic diagnostics and technologies, discover the optimal SNP panels for estimation of CHD risk and develop the prototypes of gene diagnostic tests and algorithms for prevention and treatment of dyslipidemia.
1) Identification and validation of genetic markers for diagnostic tests
2) Development of new genotyping methods
3) Development of gene diagnostic service and prevention/therapy algorithm available in health institutions in Latvia
4) Development of genotyping test prototypes for dyslipidemia and cardiovascular disease
Project will develop genotyping test and new technologies for estimation of common SNPs and familial forms of dyslipidemia involved in predisposition to multifactorial dyslipidemia for prediction of CHD risk. Validated and certified genotyping service will be developed in frame of project in Latvian Genome Centre. Service will be available for Latvian and foreign hospitals and health care practitioners and will be maintained after the realisation of the project.